期刊文献+

柳氮磺胺吡啶联合甲氨蝶呤治疗类风湿关节炎观察 被引量:3

下载PDF
导出
摘要 目的探讨治疗类风湿关节炎经济、有效、安全的治疗方案。方法将90例类风湿关节炎患者分为2组,联用组予甲氨蝶呤联合柳氮磺胺吡啶治疗,对照组予甲氨蝶呤联合帕夫林治疗,观察2组患者的临床疗效及实验室指标。结果联用组与对照组总有效率分别为94%和64%,联用组显著优于对照组(P<0.01)。结论柳氮磺胺吡啶联合甲氨蝶呤治疗类风湿关节炎较帕夫林联合甲氨蝶呤更加经济、有效。
作者 张俊霞
出处 《现代中西医结合杂志》 CAS 2011年第26期3306-3306,共1页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献2

  • 1施桂英 栗占国.关节炎概要[M].北京:中国医药科技出版社,2001.327-348.
  • 2栗占国.风湿病[M].北京:中国中医药科技出版社,2003.

共引文献38

同被引文献22

  • 1冯芳军,王香玲.类风湿性关节炎的研究进展[J].中医杂志,2011,52(S1):201-203. 被引量:4
  • 2Lee HJ,Waller RD,Stebbings S. The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis:a preliminary study[J].Int J Rheum Dis,2010,(01):48-54.
  • 3Hail N Jr,Chen P,Bushman LR. Teriflunomide (leflunomide) promotes cytostatic,antioxidant,and apoptotic effects in transformed prostate epithelial cells:evidence supporting a role for teriflunomide in prostate cancer chemoprevention[J].Neoplasia,2010,(06):464-475.
  • 4Gaujoux-Viala C,Smolen JS,Landewé R. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis[J].Annals of the Rheumatic Diseases,2010,(06):1004-1009.
  • 5van der Leeden M,Dahmen R,Ursum J. Prediction of walking disability by disease-related factors in patients with rheumatoid arthritis[J].JOURNAL OF REHABILITATION MEDICINE,2010,(05):506-510.
  • 6中华医学会风湿病学分会. 类风湿性关节炎诊治指南(草案) [J]. 中华风湿病杂志, 2003, 7(4): 251-251.
  • 7白人驹. 医学影像诊断学 [M]. 第2版. 北京: 人民卫生出版社, 2006: 747.
  • 8Danning C L, Boumpas D T. Commonly used disease-modifying antirheumatic drugs in the treatment of inflammatory arthritis:an update on mechanisms of action [J]. Clin Exp Rheumatol, 1998, 16(5): 595-604.
  • 9Lee C K, Lee E Y, Chung S M, et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappa B, osteoprolegerin, and receptor activator of nuclear factor kappaB ligand [J]. Arthritis Rheum, 2004, 50(12): 383l-3843.
  • 10Setoguchi N, Takamura N, Fujita K, et al. A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis [J]. Biopharm Drug Dispos, 2013, 34(2): 125-136.

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部